Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13217MR)

This product GTTS-WQ13217MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13217MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14929MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ11074MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ14052MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ3791MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ13902MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ7168MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ9571MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ13820MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-10987
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW